U.S. Markets closed
  • S&P Futures

    4,586.00
    +19.75 (+0.43%)
     
  • Dow Futures

    34,522.00
    +65.00 (+0.19%)
     
  • Nasdaq Futures

    16,241.50
    +91.00 (+0.56%)
     
  • Russell 2000 Futures

    2,216.20
    +18.90 (+0.86%)
     
  • Gold

    1,772.30
    -1.30 (-0.07%)
     
  • Silver

    22.61
    -0.15 (-0.68%)
     
  • EUR/USD

    1.1325
    -0.0014 (-0.1246%)
     
  • 10-Yr Bond

    1.4430
    -0.1610 (-10.04%)
     
  • Vix

    27.19
    +10.08 (+58.91%)
     
  • GBP/USD

    1.3297
    -0.0005 (-0.0359%)
     
  • USD/JPY

    113.4900
    +0.3100 (+0.2739%)
     
  • BTC-USD

    57,216.61
    -31.14 (-0.05%)
     
  • CMC Crypto 200

    1,468.81
    +0.88 (+0.06%)
     
  • FTSE 100

    7,059.45
    -231.75 (-3.18%)
     
  • Nikkei 225

    27,918.21
    +96.45 (+0.35%)
     

REVANCE THERAPEUTICS INVESTIGATION: Block & Leviton Is Investigating Revance Therapeutics, Inc. For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

BOSTON, Oct. 22, 2021 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Revance Therapeutics, Inc. (NASDAQ: RVNC) for potential securities law violations. Investors who have lost money in their Revance Therapeutics, Inc. investment should contact the firm to learn more about how they might recover those losses. For more details, visit https://www.blockleviton.com/cases/rvnc.

What is this all about?

On October 15, 2021, the U.S. Food and Drug Administration (FDA) issued a complete response letter (CRL) to Revance Therapeutics, Inc., citing deficiencies found during an inspection at the Company’s manufacturing facility for its wrinkle injection treatment, DaxibotulinumtoxinA.

Previously, shares of Revance Therapeutics fell over 25% in intraday trading on October 12, 2021 after Form 483 was posted to the FDA’s website. Shares fell over 30% in after hours trading on October 15, 2021 following news of the FDA letter.

Who is eligible?

Anyone who purchased Revance Therapeutics, Inc. stock and has lost money may be eligible, whether or not they have sold their investment. Investors should contact Block & Leviton to learn more.

What is Block & Leviton doing?

Block & Leviton is investigating whether the Company committed securities law violations and may file an action to attempt to recover losses on behalf of investors who have lost money.

What should you do next?

If you've lost money on your investment, you should contact Block & Leviton to learn more via our case website, by email at cases@blockleviton.com, or by phone at (617) 398-5600.

Why should you contact Block & Leviton?

Many law firms have issued releases about this matter; most of those firms do not actually litigate securities class actions. Block & Leviton is a law firm that actually litigates cases. We are dedicated to obtaining significant recoveries on behalf of defrauded investors through active litigation in the federal courts across the country. Many of the nation's top institutional investors hire us to represent their interests. You can learn more about us at our website, www.blockleviton.com, or call (617) 398-5600 or email cases@blockleviton.com with any questions.

This notice may constitute attorney advertising.

CONTACT:
BLOCK & LEVITON LLP
260 Franklin St., Suite 1860
Boston, MA 02110
Phone: (617) 398-5600
Email: cases@blockleviton.com

SOURCE: Block & Leviton LLP
www.blockleviton.com